NCT06391918终止1 期
A Phase 1 Study of GEN2 in Adult Patients With Locally Advanced or Metastatic Solid Tumor Malignancies
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 37
- 试验地点
- 7
- 主要终点
- Determine the recommended phase 2 dose (RP2D) of GEN2 by intravenous infusion and intratumoral injection.
研究概览
简要总结
Protocol GVO-1102 is a phase 1, open label, multi-center study in adult patients with locally advanced or metastatic solid tumors. This study includes two parts: dose escalation and dose expansion. In the dose escalation phase, GEN2 will be administered at increasing dose levels via intravenous infusion or intratumoral injection on Days 1, 3 and 8 every 4 weeks. Valganciclovir will start dosing on Day 12 and continue for 10 days (through Day 21). Once a recommended dose has been defined in approximately 35-45 patients, the dose expansion phase will initiate to further assess intravenous administration of GEN2 in specific tumor types. Approximately 15 patients per tumor type will be enrolled in the intravenous dose expansion phase.
详细描述
GEN2 is a non-replicating off-the-shelf gene therapy vector product being developed as a cancer immunotherapy to activate a patient's immune system against their personal cancer antigens (neoantigens). The vector payload encodes for a suicide gene, an enhanced viral thymidine kinase enzyme (HSV-eTK), which in the presence of a prodrug, valganciclovir, causes the tumor to release patient specific tumor antigens. These neoantigens in the presence of a human immune modulator cytokine, granulocyte-macrophage colony-stimulating factor (hGM-CSF), results in the generation of immune effector cells. These effector cells maintain continually amplifying therapeutic immune responses as more tumor cells are killed and release antigen and will potentially kill any new tumor metastases that arise.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients with a locally advanced or metastatic solid tumor that has progressed or was non-responsive to prior therapy
- •Measurable disease as determined by response evaluation criteria in solid tumors (RECIST) v1.
- •At least 18 years of age.
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0 -
- •For patients with HCC: Child-Pugh Class A
- •Available archived tumor tissue sample or a lesion that can be safely biopsied if the archived sample is not available.
- •Adequate renal, liver and bone marrow function.
- •Ability to swallow VGCV tablets.
- •Willingness of men and women of child-bearing potential (WCBP) to observe conventional and highly effective birth control for the duration of treatment and for 12 months following the last dose of study treatment. Patients who are pregnant or lactating are excluded.
- •For the dose expansion phase: Patients with hepatocellular carcinoma or cutaneous malignancy: no more than 2 prior systemic regimens for metastatic disease. Patients with breast cancer: no more than 2 prior cytotoxic regimens for metastatic disease (single-agent hormone therapy or hormone-based doublets do not count). Patients with cutaneous malignancies includes patients with melanoma, cutaneous squamous cell carcinoma, basal cell carcinoma and Merkel cell carcinoma.
- •For the intratumoral injection dose escalation phase: patients with cutaneous malignancy, including patients with melanoma, cutaneous squamous cell carcinoma, basal cell carcinoma and Merkel cell carcinoma. Patients must have at least 1 measurable and injectable lesion and an additional site of measurable distant metastases for assessment of systemic immune response to therapy. Patients may not have received prior treatment with oncolytic therapy. Patients for whom tyrosine kinase inhibitor therapy would be considered standard of care should have received these agents prior to enrollment in this trial. Patients may not have a history of significant bleeding diathesis.
排除标准
- •Investigational agent or anticancer therapy within 28 days or 5 elimination half-lives prior to Cycle 1 Day
- •Prior receipt of talimogene laherparepvec (TVEC) or any other oncolytic virus (including but not limited to RP1, RP2, or BNT111).; prior receipt of a live vaccine within 28 days prior to Cycle 1 Day
- •Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of enrollment (alopecia and other nonacute toxicities are not exclusionary)
- •Washout from prior major surgery and radiotherapy (less than 28 days)
- •Symptomatic primary central nervous system (CNS) tumor or metastases; symptomatic leptomeningeal carcinomatosis; untreated spinal cord compression. Patients with CNS lesions may be eligible if CNS lesions are asymptomatic or if neurological symptoms are stable, the patient is not receiving steroids to manage CNS symptoms, and no CNS surgery or radiation has been performed for 28 days (14 days for stereotactic radiation).
- •Active uncontrolled systemic bacterial, viral, or fungal infection, which in the opinion of the Investigator makes it undesirable for the patient to participate in the trial
- •Clinically significant active malabsorption syndrome or other conditions such as refractory nausea and vomiting, external biliary shunt, or significant bowel resection likely to affect gastrointestinal absorption of valganciclovir
- •Known contraindications to the ganciclovir class
- •For patients with hepatocellular carcinoma, patients with active hepatitis B are excluded; patients with evidence of prior exposure who have a negative hepatitis surface antigen (HbsAg) and who do not require antiviral therapy are allowed. Patients with hepatitis C are allowed but may not be on antiviral therapy during study participation and for two weeks prior to Cycle 1 Day
- •Known HIV positivity
- •Current treatment with systemic steroids at or above 10 mg/day of prednisone (or its equivalent). Inhalational and topical steroids are acceptable
结局指标
主要结局
Determine the recommended phase 2 dose (RP2D) of GEN2 by intravenous infusion and intratumoral injection.
时间窗: First 28 days.
The RP2D will be determined by evaluating the number of subjects with treatment related adverse events and Dose Limiting Toxicities
次要结局
- Safety and tolerability as assessed by adverse event monitoring(Up to 24 months)
- Pharmacokinetics (PK) - Intravenous Administration Cohorts Only: area under the concentration-time curve from the time of dosing to 48 hours after dosing (AUC48h)(Up to 24 months)
- PK - Intravenous Administration Cohorts Only: Maximum Concentration (Cmax)(Up to 24 months)
- To assess replication competent retrovirus (RCR) in peripheral blood mononuclear cells (PBMCs)(Up to 36 months)
- To assess vector integration into genomic deoxyribonucleic acid (DNA) of PBMCs(Up to 36 months)
- Overall response rate (ORR) by RECIST 1.1 (Response Evaluation in Solid Tumors Version 1.1) by Investigator Review(Up to 24 months)
- Disease control rate including a best overall response of Complete Response (CR), Partial Response (PR) or stable disease (SD)(Up to 24 months)
- Duration of response (DOR)(Up to 24 months)
- Assess the immunogenicity of GEN2(Up to 24 months)
研究者
研究点 (7)
Loading locations...
相似试验
招募中
1 期
First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid TumorsSolid Tumor, AdultNCT06622486Egle Therapeutics50
招募中
1 期
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor MalignanciesCutaneous MelanomaNon-Small Cell Lung CancerNCT05669430GV20 Therapeutics268
已完成
2 期
Gemcitabine Plus Cisplatin Single Dose Versus Split Dose in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer After Failure of Anthracyclines and/or TaxanesMetastatic Breast CancerNCT00192101Eli Lilly and Company100
招募中
2 期
To Evaluate OBI-833/OBI-821 in Patients With Locally Advanced, Globo H-Positive Esophageal Cancer for RecurrenceEsophageal CancerNCT05376423National Taiwan University Hospital60
终止
1 期
A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid TumorsEGFR Positive Solid TumorsNCT01963715ImmunoGen, Inc.20
相关资讯
GenVivo Reports Positive Phase 1 Results for GEN2 Off-the-Shelf Cancer Immunotherapy- GenVivo's GEN2 demonstrated strong safety profile with no dose-limiting toxicity or treatment-related discontinuations in 23 patients with advanced solid tumors.
- The off-the-shelf mRNA vector showed dose-dependent increases in immunocytokines and vector persistence, confirming its dual mechanism of action through HSV-eTK and GM-CSF.
- GEN2's intravenous administration offers significant advantages over intratumoral approaches by enabling treatment of advanced disease with distant metastases.
- Development of neutralizing antibodies at higher doses presents a challenge, with alternate dosing schedules and premedication strategies under evaluation.10 months agoGenVivo Reports Promising Phase 1 Data for GEN2 and Preclinical Results for GEN-1013 Cancer Immunotherapies at ASGCT 2025- GenVivo's lead candidate GEN2, a non-replicating mRNA vector therapy, demonstrates favorable safety profile with minimal toxicity and encouraging pharmacodynamic activity in Phase 1 trials for solid tumors.
- GEN-1013, the company's preclinical IL-12 encoding therapy, showed remarkable efficacy in murine cancer models with 89% of treated animals reaching study endpoints compared to just 11% in control groups.
- Both therapies leverage GenVivo's innovative vector platform that activates patients' immune systems against their own tumor antigens, with GEN-1013 advancing toward IND filing by mid-2026.last year